ENTA Stock Forecast: Enanta Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$7.61
−4.64% on the day

The 6 Wall Street analysts covering Enanta Pharmaceuticals, Inc. hold a median 12-month price target of $20 — +162.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 79 of 100 as at 21 Nov 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$232.4M
Ticker Nerd rank
79/ 100
Median analyst target
$20
Analysts covering
6
Revenue$14.4M−21.6% y/y
Operating income−$17.2M
Net income−$19.5M
Free cash flow−$10.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−30.8%
1M
−34.8%
YTD
−51.7%
1Y
−37.3%
From 52W high
−54.8%
From 52W low
0.0%
$8
$17
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Enanta Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
79/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
88
Accruals
79
Growth
77
Value
76
Issuance
64
Volatility
53
Momentum
53
Revisions
25

Quality (88): The business earns solid, repeatable profits on what it owns.

Revisions (25): Analysts have, on balance, been cutting their forecasts.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ENTA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ENTA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Jan 26Apr 26Jul 26Oct 26ENTAHigh $32Median $20Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says6 analysts
6
Buy
0
Hold
0
Sell
$17
Low
$20
Median
$32
High

The green dot is the last close — the median target sits +162.8% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
20 Nov 2026JP MorganMaintainsOverweight$19 → $17
23 Sept 2026HC Wainwright & Co.ReiteratesBuy$20
23 June 2026HC Wainwright & Co.ReiteratesBuy$20
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
14 Nov 2025JP MorganInitiatesOverweight—
1 Oct 2025JefferiesUpgradeBuy—
30 Sept 2025WestPark CapitalMaintainsBuy—
15 Sept 2025Evercore ISI GroupMaintainsOutperform—
2 Sept 2025WestPark CapitalInitiatesBuy—
12 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
28 July 2025HC Wainwright & Co.AssumesBuy$20
3 June 2025JMP SecuritiesMaintainsMarket Outperform—
14 May 2025JMP SecuritiesMaintainsMarket Outperform—
11 Feb 2025HC Wainwright & Co.ReiteratesBuy—
11 Feb 2025JMP SecuritiesReiteratesMarket Outperform—
24 Dec 2024HC Wainwright & Co.MaintainsBuy—
26 Nov 2024BairdMaintainsOutperform—
26 Nov 2024JMP SecuritiesReiteratesMarket Outperform—
10 Oct 2024HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ENTA.

Market Radar

This page is one stock. Monday covers all of them.

ENTA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ENTA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Enanta Pharmaceuticals, Inc. returned −37.3% against +6.9% for the S&P 500, dividends included.

ENTA vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26ENTAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ENTA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
3.5×

Cheaper than 30% of US stocks

Price / book
2.8×

Cheaper than 33% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−99.0%

Higher than 14% of US stocks

Net margin
—
Returns & dividend
Return on equity
−94.2%

Higher than 14% of US stocks

Return on assets
−14.0%

Higher than 23% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Enanta Pharmaceuticals, Inc. has a market value of $232.4M and an enterprise value of $215.8M.

  • Revenue in the twelve months to 30 June 2026: $65.3M. The latest quarter shrank 21.6% year on year.

  • Net income over the same four quarters: −$63.2M, a −96.9% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.41.

  • Free cash flow in the twelve months to 30 June 2026: −$36.9M.

  • Shares outstanding: 29.1M.

  • Enanta Pharmaceuticals, Inc. employs 74 people — $882K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

ENTA and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ENTAEnanta Pharmaceuticals, Inc.$232.4M79
IMRXImmuneering Corp.$218.9M48
KROSKeros Therapeutics, Inc.$218.5M83
SCTXScribe Therapeutics, Inc.$227.7M10
PYXSPyxis Oncology, Inc.$216.2M74
ARCTArcturus Therapeutics Holdings, Inc.$211.7M74
RCKTRocket Pharmaceuticals, Inc.$211.0M36

Take a look at ENTA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Enanta Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ENTA

What is the ENTA stock price forecast for 2026-2027?

The 6 Wall Street analysts covering Enanta Pharmaceuticals, Inc. have a median 12-month price target of $20, with estimates ranging from $17 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ENTA stock a buy right now?

Of the 6 analysts covering Enanta Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Enanta Pharmaceuticals, Inc. 79 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ENTA?

As at 21 Nov 2026, Enanta Pharmaceuticals, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).

Will ENTA stock go up?

No one can know that. What the data says: the median 12-month target from 6 analysts implies +162.8% from the last close, and Ticker Nerd's factor model ranks Enanta Pharmaceuticals, Inc. 79 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ENTA stock forecast for 2030?

No analyst covering Enanta Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ENTA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $32 over the next 12 months.

How has ENTA stock performed over the past year?

Enanta Pharmaceuticals, Inc. returned -37.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Enanta Pharmaceuticals, Inc. do?

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions.

Company

About Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on discovering and developing small molecule therapies for viral infections and immunological diseases. Its current portfolio centers on virology and immunology, with programs spanning respiratory syncytial virus, hepatitis B, and other infectious or inflammatory conditions. Enanta also generates value through its collaboration with AbbVie, including royalty interests tied to glecaprevir, a component of a hepatitis C treatment regimen marketed by AbbVie. The company’s work combines medicinal chemistry, drug discovery, and clinical development to advance oral therapies aimed at areas with significant unmet medical need. Headquartered in Watertown, Massachusetts, Enanta Pharmaceuticals plays a specialized role in the biotechnology market by supporting both partnered products and its own pipeline of investigational medicines.

CEO Dr. Jay R. Luly Ph.D. · 74 employees · United States · https://www.enanta.com